Information Provided By: 
Fly News Breaks for February 7, 2017
FLXN
Feb 7, 2017 | 11:12 EDT
BMO Capital analyst Gary Nachman noted that Flexion did not receive a priority review for its NDA for Zilretta, but adds that he had always assumed a standard 10-month review and is confident in the drug receiving a "timely approval" by the time of its PDUFA date of Oct. 6. Nachman reiterates the firm's Outperform rating on Flexion shares.
News For FLXN From the Last 2 Days
There are no results for your query FLXN
